The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...
The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...
A study from Spain found a subcutaneous tocilizumab biosimilar to be cost-effective when treating patients with rheumatoid ...
The US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz), from US pharma major Eli Lilly, for the ...